Търсене на изпитвания

Намерени 4,436 изпитвания Стр. 113 от 222

Набира участници

Efficacy of Music-Based Telerehabilitation After Stroke

Stroke

The goal of this clinical trial is to learn if a music-based telerehabilitation intervention implemented at home works to treat different kinds of neurological deficits caused by stroke. The main questions it aims to answer are: 1) Can the music intervention improve recovery of cognitive, verbal, motor, and emotional deficits after stroke, 2) can the music intervention enhance structural and functional recovery of the brain, and (3) how different demographic, musical, and clinical background factors affect the way the music intervention works. Researchers will compare the music intervention to standard (usual) care to see if the music intervention works to treat the deficits caused by stroke. Subjects are stroke patients who will participate either in the music intervention 5 times/week for 10 weeks in addition to standard care or receive standard care only. During the trial, the subjects will undergo neuropsychological testing and magnetic resonance imaging (MRI) three times: at baseline (before the intervention), at 3-month stage (immediately after the intervention), and at 6-month stage (3 months after the intervention).

Начало: 01.02.2025 Край: 01.12.2028 Възраст: 30–80 г.

Finland Teppo Sarkamo NCT06804304

Набира участници

Long-term Safety of Nipple Sparing Mastectomy in Women With High Penetrance Breast Cancer Susceptibility Genes in Breast Cancer

Breast Cancer Surgery

Patients with a germline pathogenic variant (GPV) in high-penetrance breast cancer susceptibility genes who are considering risk reducing mastectomy (RRM) often strongly desire to keep their nipple areola complex but inquire as to whether it is safe to do so. Relative to traditional or skin sparing mastectomy (SSM) techniques, nipple sparing mastectomy (NSM) is associated with improved psychosocial and sexual well-being and is significantly better for body image and reducing feelings of disfigurement. Despite this, guidelines have yet to endorse the use of NSM over other RRM techniques, stating that more data and longer follow-up are needed to confirm it as a safe and effective strategy in GPV carriers. As NSM was not routinely adopted in high-risk patient populations undergoing RRM before 2010, there has been little data to inform the long-term oncologic safety of NSM. Well-designed studies have reported low to negligible rates of subsequent breast cancer in BRCA1/2 carriers following NSM, but have been limited by short median follow-up of less than 3 years. The current study is designed to confirm, with longer follow-up, prior findings on the oncologic safety of NSM in unaffected BRCA1/2 carriers. The investigators will also expand data to other high-penetrance GPV carriers, including PALB2, CDH1, PTEN, and TP53, for whom there is little-to-no data on outcomes following RRM.

Начало: 01.02.2025 Край: 01.02.2028 Възраст: 18–90 г.

Australia, Belgium, Canada +2 Sir Mortimer B. Davis - Jewish General Hospital NCT06888388

Набира участници Фаза 3

Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE

Hereditary Angioedema (HAE)

This is a Phase 3, multicenter, long-term, open-label study to evaluate the safety and efficacy of once-daily orally administered deucrictibant extended-release tablet for prophylaxis to prevent angioedema attacks in participants aged ≥12 years with Hereditary Angioedema

Начало: 01.02.2025 Край: 01.12.2028 Възраст: от 12 г. Лечение

Australia, Bulgaria, Canada +10 Pharvaris Netherlands B.V. NCT06679881

Набира участници Фаза 2

A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)

T-cell Acute Lymphoblastic Leukemia Lymphoblastic Lymphoma

The T-RRex study evaluates the efficacy of WU-CART-007 for patients with Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL)/Lymphoblastic Lymphoma (LBL) and to WU-CART-007 as a therapy to induce complete Minimum Residual Disease (MRD) negative response

Начало: 31.01.2025 Край: 30.12.2028 Възраст: от 1 г. Лечение

Australia, United States Wugen, Inc. NCT06514794

Набира участници

A Cohort Study of the Efficacy and Safety of Biologics in Patients With ABPA

ABPA Biologics Allergic Bronchopulmonary Aspergillosis (ABPA) Cohort Study +2

To evaluate the efficacy and safety of biological agents in patients with allergic bronchopulmonary aspergillosis.

Начало: 31.01.2025 Край: 31.12.2028 Възраст: от 18 г.

China Qianfoshan Hospital NCT07362693

Набира участници Фаза 3

A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)

Hidradenitis Suppurativa

The purpose of this study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) Dose A and Dose B compared to placebo in participants with moderate to severe hidradenitis suppurativa (HS).

Начало: 31.01.2025 Край: 18.01.2028 Възраст: 12–100 г. Лечение

Argentina, Australia, Bulgaria +15 Novartis Pharmaceuticals NCT06799000

Набира участници Фаза 1/2

Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis

Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer

This is a phase Ib/II study evaluating the safety and efficacy of zunsemetinib (ATI-450) with capecitabine in patients with hormone receptor-positive and HER2-negative (HR+/HER2-) metastatic breast cancer (MBC).

Начало: 30.01.2025 Край: 31.05.2032 Възраст: от 18 г.

United States Washington University School of Medicine NCT06374459

Набира участници Фаза 2

Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute Leukemia

Acute Myeloid Leukemia Acute Lymphoblastic Leukemia Transplantation, Stem Cell Conditioning Therapy

This project is a prospective, single-center, randomized controlled clinical study. The subjects were high-risk or relapsed/refractory AML or ALL patients aged ≤ 65 years diagnosed by bone marrow cell morphology, immunology, genetics and therapeutic efficacy evaluation. The TmBU scheme or modified Bu/Cy (mBuCy) scheme was used for pretreatment in allo-HSCT. The primary endpoint of the study was the 2-year cumulative incidence of relapse (CIR) after allo-HSCT, and the secondary endpoints were 2-year overall survival rate (OS), progressing-free survival rate (PFS), non-relapse mortality rate (NRM), graft-versus-host disease (GVHD)-free relapse-free survival (GRFS) rate.

Начало: 30.01.2025 Край: 30.01.2030 Възраст: 15–65 г.

China The First Affiliated Hospital of Soochow University NCT06816134

Набира участници Фаза 2

efficacy and safety of the use of regulatory T cells in immune hyperactivation in patients with COVID-19 and/or acute respiratory distress syndrome

immune hyperactivation in COVID-19 patients and/or acute respiratory distress syndrome

Trial status: Authorised

Начало: 30.01.2025 Възраст: 18–64 г.

Spain Fundacion Para La Investigacion Biomedica Del Hospital 2024-519799-25-00

Набира участници Фаза 1

Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RZ-629 in Healthy Subjects and T2D

Diabetes

The main purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) biomarkers in single ascending doses (SAD), food effect, and multiple doses studies of RZ-629 in healthy participants and T2D.

Начало: 30.01.2025 Край: 20.02.2026 Възраст: 18–65 г. Лечение

Australia Rezubio Pharmaceuticals Co., Ltd. NCT06829563

Набира участници Фаза 1/2

A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

Chronic Lymphocytic Leukaemia Small Lymphocytic Lymphoma Mantle-cell Lymphoma Large B-cell Lymphoma +1

The purpose of this study is to assess the safety and efficacy of surovatamig (formerly AZD0486) administered as monotherapy or in combination with other anticancer agents in participants with hematological malignancies.

Начало: 30.01.2025 Край: 11.06.2029 Възраст: от 18 г. Лечение

Australia, China, Czechia +9 AstraZeneca NCT06564038

Набира участници Фаза 1/2

Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)

Solid Tumors Gastric Cancer Non-Small Cell Lung Cancer (NSCLC) Pancreatic Cancer +1

The PROCEADE PanTumor study aims to investigate M9140 in multiple tumor types which express carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) and it is therefore designed as a matrix study. This study aims to assess the antitumor activity, tolerability, safety, and pharmacokinetics (PK) of M9140 as monotherapy or in combination treatments in adult participants with locally advanced/metastatic CEACAM5 expressing tumors. There will be 3 substudies under this Master Protocol that may be conducted in parallel. * PROCEADE PanTumor: A Phase 1b/2, Multicenter, Open-Label Study of Anti-CEACAM5 Antibody-Drug Conjugate M9140 in Participants with Advanced Gastric Cancer (Substudy GC); * PROCEADE PanTumor: A Phase 1b/2, Multicenter, Open-Label Study of Anti-CEACAM5 Antibody-Drug Conjugate M9140 in Participants with Advanced Non-Small Cell Lung Cancer (Substudy NSCLC); * PROCEADE PanTumor: A Phase 1b/2, Multicenter, Open Label Study of Anti-CEACAM5 Antibody-Drug Conjugate M9140 in Participants With Advanced Pancreatic Cancer (Substudy PDAC).

Начало: 29.01.2025 Край: 23.12.2027 Възраст: от 18 г. Лечение

Australia, Austria, China +7 EMD Serono Research & Development Institute, Inc. NCT06710132

Набира участници Фаза 2/3

FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

Metastatic Head and Neck Squamous Cell Carcinoma Recurrent Head and Neck Squamous Cell Carcinoma

Ficerafusp alfa is directed against two targets, Epidermal Growth Factor Receptor (EGFR) and Transforming Growth Factor beta (TGF-β). This study intends to evaluate the safety and efficacy of ficerafusp alfa in combination with pembrolizumab versus placebo with pembrolizumab in 1L PD-L1-positive, recurrent or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC).

Начало: 28.01.2025 Край: 01.07.2029 Възраст: от 18 г. Лечение

Australia, Belgium, Canada +10 Bicara Therapeutics NCT06788990

Набира участници

Ending the HIV Epidemic: An All-facility Intervention for Patient and Healthcare Staff Well-being

Stigma HIV Well-Being, Psychological

The scope of this study is to engage Ryan White HIV/AIDS Program (RWHAP) funded organizations in the South/East US to co-develop context-responsive programs utilizing evidence-informed interventions to reduce stigma against living with HIV (PLH) who have difficulties accessing and remaining engaged in life-saving treatment. Five RWHAP clinics will be selected for this trial. Clinic members will participate in interactive trainings to raise awareness of and reduce stigma, from the clinic policy level to individual attitudes. Clinic members and select patients will complete self-administered surveys every 6 months over 24 months.

Начало: 27.01.2025 Край: 01.04.2028 Възраст: от 18 г.

United States Columbia University NCT05785169

Набира участници Фаза 3

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

Diffuse Large B-Cell Lymphoma

The purpose of this study is to evaluate if zilovertamab vedotin with standard treatment can help people live longer without the cancer growing or spreading than people who receive standard treatment alone.

Начало: 27.01.2025 Край: 29.03.2032 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +32 Merck Sharp & Dohme LLC NCT06717347

Набира участници

Uncovering Genes Behind Cartilage Tumors and Vascular Anomalies Using Genomic Sequencing

Enchondromatosis

Background: Ollier disease (OD) and Maffucci syndrome (MS) are rare disorders that increase the risk of cancers in cartilage tissue. These tumors can lead to severe skeletal deformities beginning in childhood. People with OD or MS are also at an increased risk of blood vessel disorders and specific cancers. Researchers want to learn more about what causes these disorders. Objective: To understand the genetic causes of OD and MS. Eligibility: People aged 2 years and older who have OD or MS with cartilage tumors or blood vessel disorders. Design: Participants will stay at the NIH clinic for 5 days. They will undergo these procedures: A physical exam with blood tests. DXA (dual-energy X-ray absorptiometry) scan. The DXA scan measures the density of bones. Participants will lie on a table while a machine uses low-level X-rays to scan their body. MRI (magnetic resonance imaging) scan. An MRI uses strong magnets to take pictures of the tissues inside the body. Participants will lie on a table that slides into a large tube. A contrast dye may be injected through a needle inserted into a vein in the arm. X-rays. Some participants may have full-body X-rays instead of an MRI. X-rays take pictures of bones and other internal tissues and organs, such as the heart, lungs, and airways. PET (positron emission tomography) and CT (computed tomography) scans. Adult participants will have 2 other scans. The PET scan will include a radioactive injection into a vein. They will also have a full-body CT scan.

Начало: 27.01.2025 Край: 31.12.2030 Възраст: 2–100 г.

United States Eunice Kennedy Shriver National Institute of Child Heal NCT06749366

Набира участници Фаза 2/3

A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia

Narcolepsy Type 1 Narcolepsy Type 2 Idiopathic Hypersomnia

The purpose of this study is to continue to measure the safety, tolerability, and durability of treatment effect in subjects with Narcolepsy Type 1 (NT1), Narcolepsy Type 2 (NT2), or Idiopathic Hypersomnia (IH) when taking ALKS 2680 tablets.

Начало: 27.01.2025 Край: 01.06.2028 Възраст: 18–70 г. Лечение

Australia, Belgium, Czechia +5 Alkermes, Inc. NCT06767683

Набира участници

Multidimensional Predictive Modeling to Understand Mechanisms of Exercise Response Heterogeneity in Older Adults (M3AX)

Aging Aging Well

Aging-related functional declines are thought to be caused by hallmark biological processes that ultimately manifest in physical, mental, and metabolic impairments that compromise healthspan and quality of life. Exercise is a multipotent treatment with promise to mitigate most aging hallmarks, but there is substantial variability in exercisƒe responsiveness. Combining endurance and resistance training in alignment with public health guidelines will be used to better understand variable exercise responsiveness in older adults with the ultimate goal of improving each older adult's capacity to attain the many health benefits of exercise.

Начало: 27.01.2025 Край: 31.08.2029 Възраст: от 60 г.

United States Florida Institute for Human and Machine Cognition NCT06507189

Набира участници Фаза 2

Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL)

Diffuse Large B Cell Lymphoma (DLBCL)

This is a phase ll study of participants with untreated diffuse large B Cell lymphoma (DLBCL).

Начало: 24.01.2025 Край: 01.11.2027 Възраст: от 18 г.

Canada University Health Network, Toronto NCT06050694

Набира участници

Prehabilitation for Patients Undergoing Lung Cancer Surgery

Lung Cancer (NSCLC)

Major surgery has been linked to running a marathon as in both represent large endeavours where the body will experience an increase in demands to supply the necessary energy. It has been alledged that, as one would train to prepare for a marathon, the same should be applied to surgery. The process of getting ready and/or fitter for surgery is frequently referred to as prehabilitation and it usually involves interventions on improving nutrition and diet, getting fit and improve emotional wellness. Prehabilitation can improve the recovery after surgery and reduce the time spent in hospital afterwards. This research seeks to determine whether a home based program of increased physical activity and breathing training can improve patients' physical and respiratory function in preparation for lung cancer surgery.

Начало: 24.01.2025 Край: 30.06.2025 Възраст: от 18 г. Лечение

Australia University of Melbourne NCT06716437

1 … 111 112 113 114 115 … 222